C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2026)

C4 Therapeutics (CCCC) posted quarterly Capital Expenditures of $38000.0 for Q1 2026, down 93.47% quarter-over-quarter from $582000.0 in Q4 2025.

C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2026) Analysis & Trends

C4 Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $38000.0 for Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at $645000.0 (up 258.33% YoY), while the FY2025 annual figure was $607000.0, up 237.22% from the prior year.
Capital Expenditures for Q1 2026 stood at $38000.0, down from $582000.0 in the prior quarter.
The five-year high for Capital Expenditures was $3.3 million in Q3 2022, with the low at -$160000.0 in Q3 2025.
The 5-year median for Capital Expenditures is $185000.0 (2025), against an average of $535266.7.
Peak annual rise in Capital Expenditures reached 14650.0% in 2025, while the deepest fall reached 193.57% in 2025.
C4 Therapeutics' Capital Expenditures stood at $1.5 million in 2022, then plunged by 89.46% to $157000.0 in 2023, then sank by 102.55% to -$4000.0 in 2024, then soared by 14650.0% to $582000.0 in 2025, then sank by 93.47% to $38000.0 in 2026.
Business Quant data shows CCCC's Capital Expenditures at $38000.0 in Q1 2026, $582000.0 in Q4 2025, and -$160000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	C4 Therapeutics	521.12 Mn	267.46 Mn	-	37,000.00

Download Data